NeuroPace (NASDAQ:NPCE) Downgraded by JPMorgan Chase & Co. to Neutral

JPMorgan Chase & Co. lowered shares of NeuroPace (NASDAQ:NPCE) from an overweight rating to a neutral rating in a research note published on Friday morning, Marketbeat reports. JPMorgan Chase & Co. currently has $9.00 price objective on the stock, down from their previous price objective of $20.00.

A number of other equities research analysts have also recently weighed in on NPCE. Mizuho initiated coverage on shares of NeuroPace in a report on Thursday, July 23rd. They issued an “outperform” rating and a $22.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of NeuroPace in a report on Tuesday, September 15th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of NeuroPace in a research report on Wednesday, July 29th. Guggenheim restated a “neutral” rating on shares of NeuroPace in a research note on Wednesday, July 29th. Finally, Weiss Ratings lowered NeuroPace from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 2nd. Five investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $15.50.

NeuroPace Stock Performance

Shares of NPCE stock opened at $7.56 on Friday. The company’s fifty day moving average price is $13.21 and its 200-day moving average price is $14.75. The stock has a market cap of $259.46 million, a PE ratio of -13.50 and a beta of 1.98. The company has a current ratio of 4.94, a quick ratio of 3.91 and a debt-to-equity ratio of 4.97. NeuroPace has a 12 month low of $5.46 and a 12 month high of $19.60.

NeuroPace (NASDAQ:NPCE) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. NeuroPace had a negative net margin of 20.00% and a negative return on equity of 110.26%. The company had revenue of $22.83 million during the quarter, compared to analysts’ expectations of $22.61 million. On average, equities analysts expect that NeuroPace will post -0.67 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NPCE. Legal & General Group Plc purchased a new stake in NeuroPace during the 2nd quarter valued at $41,000. Diversified Trust Co purchased a new position in shares of NeuroPace in the 3rd quarter worth $153,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in NeuroPace during the second quarter valued at $157,000. Bank of America Corp DE purchased a new stake in NeuroPace during the second quarter valued at $322,000. Finally, Canada Pension Plan Investment Board bought a new position in NeuroPace in the second quarter valued at about $351,000. Institutional investors own 78.83% of the company’s stock.

Recent NeuroPace Headlines

Here are a few of the latest headlines about NPCE:

• Positive Sentiment: NeuroPace reported a Q3 loss of $0.03 per share, improved from a $0.11 loss a year earlier and better than analyst estimates. Zacks Q3 earnings report
• Negative Sentiment: Q3 revenue was $23.1 million, below the cited $27.1 million analyst estimate. Revenue from the company’s RNS System grew just 1.4% year over year, signaling limited near-term growth. NeuroPace Q3 results and guidance
• Negative Sentiment: The company cut its 2026 revenue outlook to $91–$92 million, well below the roughly $100.4 million consensus estimate, reinforcing concerns about its sales trajectory. Revenue miss and lowered outlook

NeuroPace Company Profile

NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.